<DOC>
	<DOC>NCT00897104</DOC>
	<brief_summary>A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.</brief_summary>
	<brief_title>MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Rizatriptan</mesh_term>
	<criteria>Participant had at least a 6month history of migraine, with or without aura Participant was male, or if female, must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions Participant was judged to be in good health, apart from migraine Participant was Pregnant or a nursing mother Participant had a history or current evidence of drug or alcohol abuse Participant had a history or clinical evidence of cardiovascular disease Participant had a clinically significant Electrocardiography (ECG) abnormality Participant had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening Participant had received treatment with an investigational device or compound within 30 days of the study Participant typically suffered from less then 1 or more than 8 attacks of migraine per month Participant had difficulty in distinguishing his/her migraine attacks from tension or interval headaches Participant was currently taking monoamine oxidase inhibitors, methysergide or lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>